GEN-MKT-18-7897-A
Mar 29, 2017 | Biopharma, Blogs | 0 comments
Is your mind swimming with large molecule catabolism data? Do you spend hours manually processing through complex spreadsheets to match your data with theoretical biologic catabolites? Are you wasting precious time by drawing out and processing your therapeutic peptide as a small molecule? Are you worried that you could be missing something?
As a MetID expert, you are pushing the limits of drug metabolite and biotherapeutic catabolite identification to advance new drugs through ADME studies in the development pipeline. The ability to identify and understand everything in your sample, faster and more efficiently, is the defining factor in this game. The reality is that comprehensive data acquisition, processing and interpretation are the be-all and end-all. The question is how do you streamline and automate this process while achieving the ultimate confidence in results? The answer is the Advanced Biotransform Solution from SCIEX.
Our Advanced Biotransform Solution puts a completely new spin on comprehensive large molecule catabolism because it offers the most advanced, integrated metabolism software available on the market. Hard to believe? We have combined the SCIEX TripleTOF® 6600 High-Resolution QTOF System with the ultra-fast and unbiased SWATH® Acquisition, so you can be confident you are acquiring high-quality data on all detectable metabolites in your sample; nothing hides from this solution. And as if that isn’t enough, here comes the game changer. We have introduced our new MetabolitePilot™ Software 2.0, so you can take your biologic catabolism data processing beyond laborious manual spreadsheets and trying to fit your therapeutic peptide in a small molecule processing workflow and accelerated it with automated analysis.
This all-in-one industry leading metabolite identification software from SCIEX has the most sophisticated large molecule algorithms ever—automating data processing, interpretation, visualization, and reporting.
More Time for Decision Making and to Focus on ResultsNow you can employ the same automated processing and assignment for large molecule catabolites as you can for drug metabolites:
Fast, automated, and comprehensive peptide catabolism and biotransformation identification allows you to find liabilities and soft spots in the candidate molecule which may keep it from being biologically active and safe, in vivo.
Want to know more? Download our solution guide to see how we have combined our world-leading hardware, software and support to give you the most comprehensive understanding of large molecule catabolism, faster than ever before.Download Solution Guide >
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network